Which has preferable valuation and earnings, ADIL or CLRB?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is ADIL or CLRB more profitable?

Adial Pharmaceuticals' return on equity of -162.82% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% Cellectar Biosciences N/A -349.24% -153.18%

Does the media favor ADIL or CLRB?

In the previous week, Adial Pharmaceuticals and Adial Pharmaceuticals both had 2 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.96 beat Cellectar Biosciences' score of 0.47 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ADIL or VYNE?

Adial Pharmaceuticals presently has a consensus target price of $17.17, indicating a potential upside of 491.95%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Adial Pharmaceuticals is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Does the media favor ADIL or VYNE?

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Adial Pharmaceuticals and 1 mentions for VYNE Therapeutics. Adial Pharmaceuticals' average media sentiment score of 1.96 beat VYNE Therapeutics' score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LGVN or ADIL?

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for Adial Pharmaceuticals and 1 mentions for Longeveron. Adial Pharmaceuticals' average media sentiment score of 1.96 beat Longeveron's score of 0.84 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend ALVR or ADIL?

Adial Pharmaceuticals has a consensus price target of $17.17, indicating a potential upside of 491.95%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has stronger earnings & valuation, ALVR or ADIL?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is ALVR or ADIL more profitable?

AlloVir's return on equity of -71.03% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Adial Pharmaceuticals N/A -162.82% -127.58%

Is ALLR or ADIL more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Adial Pharmaceuticals N/A -162.82% -127.58%

Does the media refer more to ALLR or ADIL?

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 2 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.96 beat Allarity Therapeutics' score of 0.60 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Adial Pharmaceuticals (ADIL) Competitors

$2.90 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.90 +0.00 (+0.17%)

As of 07/2/2026 07:59 PM Eastern

Compare

ADIL vs. CLRB, VYNE, LGVN, ALVR, and ALLR

Should you buy Adial Pharmaceuticals stock or one of its competitors? MarketBeat compares Adial Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adial Pharmaceuticals include Cellectar Biosciences (CLRB), VYNE Therapeutics (VYNE), Longeveron (LGVN), AlloVir (ALVR), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry.

How does Adial Pharmaceuticals compare to Cellectar Biosciences?

Adial Pharmaceuticals (NASDAQ:ADIL) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Adial Pharmaceuticals has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

In the previous week, Adial Pharmaceuticals and Adial Pharmaceuticals both had 2 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.96 beat Cellectar Biosciences' score of 0.47 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adial Pharmaceuticals currently has a consensus price target of $17.17, suggesting a potential upside of 491.95%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 291.46%. Given Adial Pharmaceuticals' higher possible upside, research analysts clearly believe Adial Pharmaceuticals is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Adial Pharmaceuticals' return on equity of -162.82% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Summary

Adial Pharmaceuticals beats Cellectar Biosciences on 8 of the 12 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to VYNE Therapeutics?

Adial Pharmaceuticals (NASDAQ:ADIL) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Adial Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Adial Pharmaceuticals and 1 mentions for VYNE Therapeutics. Adial Pharmaceuticals' average media sentiment score of 1.96 beat VYNE Therapeutics' score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adial Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Adial Pharmaceuticals has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
VYNE Therapeutics	$570K	39.78	-$26.48M	-$0.38	N/A

Adial Pharmaceuticals presently has a consensus target price of $17.17, indicating a potential upside of 491.95%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Adial Pharmaceuticals is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Adial Pharmaceuticals beats VYNE Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Longeveron?

Longeveron (NASDAQ:LGVN) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

10.0% of Longeveron shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Longeveron has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Longeveron currently has a consensus target price of $5.50, indicating a potential upside of 696.52%. Adial Pharmaceuticals has a consensus target price of $17.17, indicating a potential upside of 491.95%. Given Longeveron's stronger consensus rating and higher possible upside, equities research analysts plainly believe Longeveron is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Adial Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Adial Pharmaceuticals' return on equity of -162.82% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for Adial Pharmaceuticals and 1 mentions for Longeveron. Adial Pharmaceuticals' average media sentiment score of 1.96 beat Longeveron's score of 0.84 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adial Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Adial Pharmaceuticals has lower revenue, but higher earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	17.92	-$22.70M	-$1.13	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

Summary

Adial Pharmaceuticals beats Longeveron on 9 of the 14 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Adial Pharmaceuticals has a consensus price target of $17.17, indicating a potential upside of 491.95%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

66.1% of AlloVir shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Adial Pharmaceuticals had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for Adial Pharmaceuticals and 0 mentions for AlloVir. Adial Pharmaceuticals' average media sentiment score of 1.96 beat AlloVir's score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Adial Pharmaceuticals	Very Positive

AlloVir's return on equity of -71.03% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Summary

Adial Pharmaceuticals beats AlloVir on 8 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Allarity Therapeutics presently has a consensus price target of $10.25, suggesting a potential upside of 682.44%. Adial Pharmaceuticals has a consensus price target of $17.17, suggesting a potential upside of 491.95%. Given Allarity Therapeutics' higher probable upside, equities analysts clearly believe Allarity Therapeutics is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 2 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.96 beat Allarity Therapeutics' score of 0.60 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adial Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Adial Pharmaceuticals has lower revenue, but higher earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	65.13	-$11.23M	-$0.72	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

Allarity Therapeutics' return on equity of -109.94% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Allarity Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Adial Pharmaceuticals beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADIL vs. The Competition

Export

Metric	Adial Pharmaceuticals	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.22M	$431.50M	$7.16B	$12.48B
Dividend Yield	N/A	3.88%	2.66%	6.52%
P/E Ratio	-0.36	3.09	28.02	24.70
Price / Sales	N/A	6,669.11	540.37	99.49
Price / Cash	N/A	13.13	49.26	57.09
Price / Book	0.61	88.67	10.96	6.46
Net Income	-$7.98M	-$96.07M	$3.57B	$337.01M
7 Day Performance	14.22%	0.17%	2.12%	1.69%
1 Month Performance	31.22%	2.10%	5.25%	3.81%
1 Year Performance	-64.42%	68.02%	33.29%	23.90%

Adial Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADIL Adial Pharmaceuticals	3.6012 of 5 stars	$2.90 flat	$17.17 +492.0%	-64.4%	$6.22M	N/A	N/A	20	News Coverage Positive News Gap Down
CLRB Cellectar Biosciences	4.3663 of 5 stars	$2.74 +5.2%	$11.00 +302.2%	-41.7%	$21.85M	N/A	N/A	10	News Coverage
VYNE VYNE Therapeutics	0.9144 of 5 stars	$0.65 +1.0%	N/A	-50.7%	$21.81M	$454K	N/A	30
LGVN Longeveron	2.8856 of 5 stars	$0.70 -2.0%	$5.50 +690.2%	-47.5%	$21.65M	$1.22M	N/A	20	Gap Up
ALVR AlloVir	N/A	$4.22 -2.4%	N/A	+90.0%	$21.26M	N/A	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADIL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. CLRB, VYNE, LGVN, ALVR, and ALLR

How does Adial Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does Adial Pharmaceuticals compare to VYNE Therapeutics?

Summary

How does Adial Pharmaceuticals compare to Longeveron?

Summary

How does Adial Pharmaceuticals compare to AlloVir?

Summary

How does Adial Pharmaceuticals compare to Allarity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. CLRB, VYNE, LGVN, ALVR, and ALLR

How does Adial Pharmaceuticals compare to Cellectar Biosciences?

Which has more risk & volatility, ADIL or CLRB?

Which has preferable valuation and earnings, ADIL or CLRB?

Does the media favor ADIL or CLRB?

Do analysts prefer ADIL or CLRB?

Do insiders and institutionals believe in ADIL or CLRB?

Is ADIL or CLRB more profitable?

Summary

How does Adial Pharmaceuticals compare to VYNE Therapeutics?

Do institutionals and insiders have more ownership in ADIL or VYNE?

Is ADIL or VYNE more profitable?

Does the media favor ADIL or VYNE?

Which has more risk & volatility, ADIL or VYNE?

Which has stronger earnings & valuation, ADIL or VYNE?

Do analysts recommend ADIL or VYNE?

Summary

How does Adial Pharmaceuticals compare to Longeveron?

Do insiders and institutionals believe in LGVN or ADIL?

Which has more volatility and risk, LGVN or ADIL?

Do analysts prefer LGVN or ADIL?

Is LGVN or ADIL more profitable?

Does the media refer more to LGVN or ADIL?

Which has higher earnings & valuation, LGVN or ADIL?

Summary

How does Adial Pharmaceuticals compare to AlloVir?

Do analysts recommend ALVR or ADIL?

Which has more risk & volatility, ALVR or ADIL?

Which has stronger earnings & valuation, ALVR or ADIL?

Do insiders and institutionals believe in ALVR or ADIL?

Does the media favor ALVR or ADIL?

Is ALVR or ADIL more profitable?

Summary

How does Adial Pharmaceuticals compare to Allarity Therapeutics?

Do analysts rate ALLR or ADIL?

Does the media refer more to ALLR or ADIL?

Which has preferable earnings and valuation, ALLR or ADIL?

Is ALLR or ADIL more profitable?

Which has more risk & volatility, ALLR or ADIL?

Do insiders & institutionals hold more shares of ALLR or ADIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools